Drugs / BGB-45035
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06342713 | Jun 2024 → Jun 2026 | atopic eczema, autoimmune disease, prurigo nodularis | BeiGene | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07100938 | Aug 2025 → May 2026 | rheumatoid arthritis | BeiGene | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-45035 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06342713 ↗ |
| Route | Oral | “Administered orally” NCT06342713 ↗ |